Bio-rad Laboratories, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NYSE
Schwartz Allison, a Director of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on September 4, 2026.
NYSE
James Barry, EVP, President, LSG of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on September 4, 2026.
NYSE
Sedat Evran, EVP, Global Supply Chain of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on September 4, 2026.
NYSE
Eva Anette Engelhardt, EVP, President, CDG of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on September 4, 2026.
NYSE
Jonathan P. Divincenzo, President & COO of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on September 4, 2026.
NYSE
Courtney C Enloe, EVP, General Counsel & Sec of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on September 4, 2026.
NYSE
Rajat Mehta, EVP, GBL Commercial Operations of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on September 4, 2026.
NYSE
Roop Kalyan Lakkaraju, EVP, Chief Financial Officer of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on September 4, 2026.
NYSE
Norman D Schwartz, Chairman & CEO, a Director and 10% owner of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on September 4, 2026.
NYSE
Norman D Schwartz, Chairman & CEO, a Director and 10% owner of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on September 1, 2026.
NYSE
Eva Anette Engelhardt, EVP, President, CDG of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on July 25, 2026.
NYSE
Bio-Rad Laboratories' EVP and CFO, Roop Kalyan Lakkaraju, acquired 1,078 shares of Class A common stock upon the vesting of restricted stock units.
NYSE
Courtney C. Enloe, EVP, General Counsel & Secretary of Bio-Rad Laboratories, Inc., acquired shares through the vesting of restricted stock units and participation in the Employee Stock Purchase Plan.
NYSE
Form 4: Bio-Rad Director Acquires Shares
Bio-Rad Laboratories Director Greg K. Hinckley acquired shares of Class A common stock upon the vesting of restricted stock units.
NYSE
Bio-Rad Laboratories Director Melinda Litherland reported transactions involving the acquisition of Class A common stock upon the vesting of restricted stock units.
NYSE
Bio-Rad Laboratories Director Jeffrey L. Edwards acquired shares of Class A common stock upon the vesting of restricted stock units.
NYSE
Director Arnold A. Pinkston of Bio-Rad Laboratories acquired shares upon the vesting of restricted stock units.
NYSE
Bio-Rad Laboratories EVP James Barry sold 699.873 shares of Class A Common Stock for approximately $306.18 per share on November 6, 2025, under a pre-arranged 10b5-1 plan.
NYSE
Bio-Rad Laboratories' President & COO, Jonathan P. DiVincenzo, acquired shares through RSU vesting and sold a portion for tax obligations.
NYSE
Sedat Evran, EVP of Global Supply Chain at Bio-Rad Laboratories, reported the vesting of 1,044 restricted stock units and the subsequent sale of 335 shares for tax obligations.
NYSE
Bio-Rad Laboratories' EVP of Global Supply Chain, Sedat Evran, reported the vesting of restricted stock units and related stock transactions.
NYSE
Bio-Rad Laboratories' EVP and CFO, Roop Kalyan Lakkaraju, disclosed the vesting of restricted stock units, the acquisition of shares, and a subsequent sale for tax obligations, alongside a new RSU grant.
NYSE
Colleen Corey, Bio-Rad's EVP of Global Human Resources, reported the vesting of 576 restricted stock units and the grant of 2,740 new units.
NYSE
Bio-Rad Laboratories EVP, James Barry, reported the vesting of restricted stock units, a subsequent tax-related sale of Class A common stock, and a new grant of restricted stock units.
NYSE
Bio-Rad Laboratories Director Allison Schwartz reported the acquisition of 914 new Restricted Stock Units and the vesting of 92 existing units, alongside related stock transactions.
NYSE
Bio-Rad Laboratories' President and COO, Jonathan P. DiVincenzo, was granted 6,850 restricted stock units vesting over four years.
NYSE
Bio-Rad Laboratories EVP, President, CDG Eva Anette Engelhardt reported the vesting of restricted stock units and related stock transactions.
NYSE
Bio-Rad Laboratories' EVP, General Counsel & Secretary, Courtney C. Enloe, reported the vesting of restricted stock units and a subsequent tax-related sale of common stock.
NYSE
Bio-Rad Laboratories' Chairman and CEO, Norman Schwartz, reported the vesting of restricted stock units and related share transactions.
NYSE
Bio-Rad Laboratories' EVP of Global Commercial Operations, Rajat Mehta, received a grant of 7,307 restricted stock units.